Atea Pharmaceuticals, Inc. · NASDAQ:AVIR
Atea Pharmaceuticals — 44th Annual J.P. Morgan Healthcare Conference (January 2026)
25 slides from Atea Pharmaceuticals's conference presentation, Jan 15, 2026
Slide 1: JP Morgan Healthcare Conference
JP Morgan Healthcare Conference 1 January 15, 2026
Slide 2: Disclaimers
DISCLAIMERS Forward-Looking Statements This presentation contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based on our curr
Slide 3: Focused Antiviral Pipeline with De-risked Phase 3 Program
Focused Antiviral Pipeline with De-risked Phase 3 Program Therapeutic/ Program Preclinical Phase 1 Phase 2 Phase 3 Milestone Indication Flaviviridae Hepatitis C Virus Ph 3 C-BEYOND trial (HCV) (US / Canada) enrollment Fixed Dose completed (n=> 880); Combination: results expected mid-2026 Bemnifosbuv
Slide 4: US New Chronic HCV Infections Continue to Increase Despite Availability of Curative Direct-Acting Antivirals
US New Chronic HCV Infections Continue to Increase Despite Availability of Curative Direct-Acting Antivirals Removal of HCV prescribing barriers by payors 4
Slide 5: BEM/RZR Potential Best-in-Class Regimen for Treatment of HCV
BEM/RZR Potential Best-in-Class Regimen for Treatment of HCV Profile 5
Slide 6: BEM/RZR: Potential Best-in-Class Treatment for HCV
BEM/RZR: Potential Best-in-Class Treatment for HCV First Head-to-Head Phase 3 Program in HCV Potential Best-In-Class Robust Phase 2 Results Phase 3 BEM / RZR vs. Treatment for HCV Achieved Primary Endpoints Active Comparator • HCV product candidate is regimen of • Phase 2 results (n=275) -- BEM and
Slide 7: BEM/RZR KOL Feedback Test-and-Treat & Market Research
BEM/RZR KOL Feedback Test-and-Treat & Market Research BEM/RZR Market Research 7
Slide 8: KOLS: BEM/RZR Profile Well Suited for Rapid Test-and-Treat Care
KOLS: BEM/RZR Profile Well Suited for Rapid Test-and-Treat Care If we're able to enlarge number of healthcare While you're waiting, they're spreading HCV. providers that treat HCV, the multiplier effect on You want to to poke a patient's finger, get a result getting treatment across the US is expone
Slide 9: Annual New HCV Infections in US Exceed Annual Treatments
Annual New HCV Infections in US Exceed Annual Treatments Test-and-Treat Can Expand Diagnosis and Treatment of HCV Infections US HCV INFECTIONS GROWING EXPANSION OF TEST-AND-TREAT MODEL OF CARE FASTER THAN TREATED PATIENTS CRITICAL TO ACCELERATE HCV ELIMINATION IN US TEST TREAT Potential US ~4 Millio
Slide 10: Highly Attractive BEM/RZR Commercial Profile
Highly Attractive BEM/RZR Commercial Profile BEM/RZR Has Potential to Become Most Prescribed Treatment in HCV Market PRESCRIBERS PAYORS MARKET Quantitative Market Research Research of Payors Covering Concentrated of High DAA Prescribers >130M Lives Prescriber Base % of patients likely to be prescrib
Slide 11: Global Phase 3 Program Update
BEM/RZR Potential Best-in-Class Regimen for Treatment of HCV Global Phase 3 Program Update 11
Slide 12: On Track: Global HCV Phase 3 Program
On Track: Global HCV Phase 3 Program C-BEYOND C-FORWARD • ~120 sites in US and Canada • Enrollment completed • ~120 sites in 17 countries outside of North America • Cirrhotic population target achieved • Enrollment completion expected mid-2026 • Results expected mid-2026 • Results expected year-end
Slide 13: Global HCV Phase 3 Program: C-BEYOND and C-FORWARD
Global HCV Phase 3 Program: C-BEYOND (US/Canada) and C-FORWARD (Outside North America) Open-label: BEM/RZR Regimen vs Active Comparator in Chronic HCV Patients Randomized (1:1) Non-Cirrhotic 8 weeks BEM/RZR FDC Chronic HCV, patients US / Canada Trial stratified by cirrhosis 1:1 Enrollment Completed
Slide 14: Predicted Median Time to Viral Clearance by Fibrosis Stage Based on Ph 2 Results
Predicted Median Time to Viral Clearance by Fibrosis Stage Based on Ph 2 Results Time to Cure Estimates Support 8-Week Treatment for Non-cirrhotic and 12-Week Treatment for Compensated Cirrhosis (BEM/RZR) (BEM/RZR) MEDIAN TIME TO LLOQ BASED ON MODEL PREDICTION: VIROLOGIC RESPONSE (VR) BASED ON MODEL
Slide 15: Phase 3 Endpoints, Patient Populations and Analyses
Phase 3 Endpoints, Patient Populations and Analyses C-BEYOND (US/CANADA) C-FORWARD (Outside North America) Primary Efficacy SVR at Week 24 mITT population SVR at Week 24 PP population Endpoint Major Secondary SVR at Week 24 PP population SVR at Week 24 mITT population Efficacy Endpoint Modified Inte
Slide 16: BEM/RZR Commercial Readiness
BEM/RZR Commercial Readiness Commercial Supply Available for Launch at NDA Approval All components and processes for large Blister card for convenience scale manufacturing are in place and patient adherence Manufacture of commercial launch supply underway Low cost of goods relative to net price Simp
Slide 17: New Program Hepatitis E Virus
New Program Hepatitis E Virus Product Candidate AT-587 17
Slide 18: Hepatitis E Virus (HEV) Overview
Hepatitis E Virus (HEV) Overview WHO estimates up to 20 million global HEV infections annually1 Foodborne transmission HEV2 Waterborne transmission HEV2 causes chronic infection in the causes acute epidemics in GT 1,2 GT 3,4 immunocompromised developing countries in developed countries HEV-1 HEV-2 H
Slide 19: Chronic HEV Infection Among Immunocompromised Individuals Can Lead to Rapid Progression to Cirrhosis
Chronic HEV Infection Among Immunocompromised Individuals with GT-3 and GT-4 Can Lead to Rapid Progression to Cirrhosis At-Risk Populations1 • Solid organ transplant recipients 15% ofchronic infected SOT recipients with HEV rapidly develop cirrhosis in 3-5 years2 • Hematopoietic stem cell transplant
Slide 20: Estimated HEV Infection Among High-Risk Populations Leads to Commercial Opportunity of $750M-$1B
Estimated HEV Infection Among High-Risk Populations in US & EU Leads to Commercial Opportunity of $750M-$1B* A growing number of patients in high-risk populations in US & EU with no approved treatment Incidence among at-risk Incidence rate of populations chronic HEV Solid Organ Transplant (SOT)1 Rec
Slide 21: AT-587: Potent Antiviral Activity Against Multiple HEV-3 Strains and Ribavirin Resistant Virus
AT-587: Potent Antiviral Activity Against Multiple HEV-3 Strains and Ribavirin Resistant Virus in Replicons EC50 VALUES (NM) AGAINST HEV STRAINS IN HUH7 CELLS HEV-3 p6 G1634R Compound HEV-3 p6 WT HEV-3 83.2.27 (RBV RAS)* Bemnifosbuvir 477 ± 121 (n=4) --- --- AT-587 86.1 ± 20.1 (n=5) 83.9 ± 1.6 142.2
Slide 22: Comparable Exposure of Active Triphosphate Metabolite Surrogate with AT-587 and Bemnifosbuvir
Comparable Exposure of Active Triphosphate Metabolite Surrogate Achieved with AT-587 and Bemnifosbuvir Following a Single Oral Dose to Rats and Monkeys Bemnifosbuvir AT-587 Surrogate Surrogate Species PK Parameter Parent Drug Species PK Parameter Parent Drug Metabolite Metabolite Dose (mg/kg) 100 Do
Slide 23: AT-587 Forms High Levels of Active Triphosphate Metabolite in Human Hepatocytes
AT-587 Forms High Levels of Active Triphosphate Metabolite (AT-9068) in Human Hepatocytes (Site of Viral Replication) Triphosphate AUC0-24h (h*pmol /106 cells) AT-9010 AT-9068 CELLS (BEM) (AT-587) Human hepatocytes 1,360 3,920 • No inhibition of α, β, γ human DNA polymerases by active triphosphate (
Slide 24: Upcoming Key Milestones Across Antiviral Pipeline
Upcoming Key Milestones Across Antiviral Pipeline BEM/RZR REGIMEN - PHASE 3 PROGRAM FOR HCV Mid-2026 Year-end 2026 2027 Ongoing • Completion of C- • Topline Phase 3 • Anticipated Q1 NDA • Two Phase 3 Trials FORWARD patient results for submission enrollment C-FORWARD • Topline Phase 3 results for C-B
Slide 25: 225 Franklin Street Suite 2100 Boston MA USA 02110
225 Franklin Street Suite 2100 Boston MA USA 02110 www.ateapharma.com 25
Atea Pharmaceuticals — 44th Annual J.P. Morgan Healthcare Conference (January 2026) on 6ix